On December 17, 2025, Emmaus Life Sciences, Inc. agreed to exchange 6,332,692 shares valued at approximately $0.38 each and a $600,000 convertible promissory note for a $3,000,000 outstanding note. This event involves significant changes to their financial obligations and stock structure.